Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07120451) titled 'Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker' on Aug. 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Advanced Ovarian Cancer
Intervention:
Drug: Senaparib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 10, 2025
Target Sample Size: 37
Countries of Recruitment:
Ch...